Outset Medical announced it received $76.5 million in Series C equity funding. A new investor, funds advised by T. Rowe Price Associates Inc., led the round, which also included participation from existing investors Fidelity Management & Research Company, Partner Fund Management LP, Warburg Pincus, Perceptive Advisors and The Vertical Group.

Outset’s technology, the Tablo Hemodialysis System, is aimed at clinics who want to develop the self-care option for patients. It can also be used in hospitals and skilled nursing facilities.

The company will use proceeds from the financing to expand the commercial introduction of the Tablo System in acute and chronic care markets in the United States.